Subtype
Pancreatic Neoplasm
CI-CAN-00001356Explore in graph →
Non-malignant988 active trials8 approved drugs63 evidence items
Loading cancer entity…
Loading cancer entity…
Subtype
CI-CAN-00001356Explore in graph →
Clinical trials
4,217 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT05009966 | Study of SYSA1801 in the Treatment of Claudin( CLDN) 18.2 Positive Advanced Malignant Solid Tumor | unknown | Phase 1 | 272 | CSPC ZhongQi Pharmaceutical Technology Co., Ltd.INDUSTRY | 1 | Oct 25, 2021 | clinicaltrials |
| NCT04928625 | A Trial of SHR-A1904 in Patients With Advanced Pancreatic Cancer | unknown | Phase 1 | 75 | Shanghai Hengrui Pharmaceutical Co., Ltd.INDUSTRY | 1 | Aug 24, 2021 | clinicaltrials |
| NCT02305186 | Safety and Immunological Effect of Pembrolizumab in Resectable or Borderline Resectable Pancreatic Cancer(UVA-PC-PD101) | unknown | Phase 1 / Phase 2 | 68 | Craig L Slingluff, JrOTHER | 1 | Aug 13, 2021 | clinicaltrials |
| NCT04764084 | Niraparib Combined With Anlotinib in Homologous Recombination Repair (HRR) Gene-mutated Advanced Solid Tumors | unknown | Phase 1 | 52 | Peking University Cancer Hospital & InstituteOTHER | 1 | Feb 21, 2021 | clinicaltrials |
| NCT03703063 | Alternative Neoadjuvant Chemotherapy in Resectable and Borderline Resectable Pancreatic Cancer | unknown | Phase 1 | 30 | Benaroya Research InstituteOTHER | 1 | Jan 27, 2021 | clinicaltrials |
| NCT04707118 | Ntraperitoneal Thermal Perfusion Combined With Chemotherapy Versus Chemotherapy | unknown | Phase 1 | 106 | Fudan UniversityOTHER | 1 | Jan 13, 2021 | clinicaltrials |
| NCT04425876 | A Study of Fluzoparib in Combination With mFOLFIRINOX in Patients With Resectable Pancreatic Cancer | unknown | Phase 1 | 74 | Jiangsu HengRui Medicine Co., Ltd.INDUSTRY | 1 | Dec 31, 2020 | clinicaltrials |
| NCT03989310 | An Open-label, Phase I/II Study of the Pan-immunotherapy in Patients With Local Advanced/Metastatic Pancreatic Cancer | unknown | Phase 1 / Phase 2 | 50 | Chinese PLA General HospitalOTHER | 1 | Dec 23, 2020 | clinicaltrials |
| NCT03507998 | Phase 1 Dose Escalation Study of CGX1321 in Subjects With Advanced Gastrointestinal Tumors | unknown | Phase 1 | 39 | Curegenix Inc.INDUSTRY | 1 | Jul 24, 2020 | clinicaltrials |
| NCT04482257 | Bioequivalence Study of Irinotecan Liposome Injection in Chinese Advanced Pancreatic Cancer. | unknown | Phase 1 | 48 | CSPC Ouyi Pharmaceutical Co., Ltd.INDUSTRY | 1 | Jul 22, 2020 | clinicaltrials |
| NCT02599662 | Intraoperative Radiation Therapy for Resectable Pancreas Cancer(IORT) | unknown | Phase 1 | 12 | Loyola UniversityOTHER | 1 | Jun 4, 2020 | clinicaltrials |
| NCT03638206 | Autologous CAR-T/TCR-T Cell Immunotherapy for Malignancies | unknown | Phase 1 / Phase 2 | 73 | Shenzhen BinDeBio Ltd.INDUSTRY | 1 | Dec 11, 2019 | clinicaltrials |
| NCT02737228 | Study of CG200745 PPA in Combination With Gemcitabine and Erlotinib for Advanced Pancreatic Cancer | unknown | Phase 1 / Phase 2 | 24 | CrystalGenomics, Inc.INDUSTRY | 1 | Jun 17, 2019 | clinicaltrials |
| NCT03941457 | Clinical Research of ROBO1 Specific BiCAR-NK Cells on Patients With Pancreatic Cancer | unknown | Phase 1 / Phase 2 | 9 | Asclepius Technology Company Group (Suzhou) Co., Ltd.INDUSTRY | 1 | May 8, 2019 | clinicaltrials |
| NCT02433626 | Study of COTI-2 as Monotherapy or Combination Therapy for the Treatment of Malignancies(COTI2-101) | unknown | Phase 1 | 51 | Critical Outcome Technologies Inc.INDUSTRY | 1 | Feb 1, 2019 | clinicaltrials |
| NCT02950064 | A Study to Determine the Safety of BTP-114 for Treatment in Patients With Advanced Solid Tumors With BRCA Mutations | unknown | Phase 1 | 95 | Placon TherapeuticsINDUSTRY | 1 | Jan 14, 2019 | clinicaltrials |
| NCT03634501 | Clinical Study on Anti-tumor Effect Induced by Activated Primary Natural Killer（NK）Cells | unknown | Phase 1 / Phase 2 | 200 | Xuanwu Hospital, BeijingOTHER | 1 | Jan 11, 2019 | clinicaltrials |
| NCT03662412 | Study of Sirolimus in Patients With Advanced Pancreatic Cancer | unknown | Phase 1 / Phase 2 | 36 | Second Affiliated Hospital, Zhejiang University, School of MedicineOTHER | 1 | Sep 7, 2018 | clinicaltrials |
| NCT02450656 | Afatinib and Selumetinib in Advanced KRAS Mutant and PIK3CA Wildtype Non-small Cell Lung Cancer(M14AFS) | unknown | Phase 1 / Phase 2 | 320 | The Netherlands Cancer InstituteOTHER | 1 | Aug 27, 2018 | clinicaltrials |
| NCT03633734 | Efficacy Evaluation of Sequential Treatment With AG and Modified Folfirinox in Metastatic Pancreatic Adenocarcinoma | unknown | Phase 1 / Phase 2 | 49 | Second Affiliated Hospital, Zhejiang University, School of MedicineOTHER | 1 | Aug 22, 2018 | clinicaltrials |
| NCT02975141 | Afatinib and Gemcitabine/Nab-paclitaxel in Metastatic Pancreatic Cancer(AFFECT) | unknown | Phase 1 | 12 | PD Dr. med. Volker HeinemannOTHER | 1 | Aug 13, 2018 | clinicaltrials |
| NCT03607643 | A Study of the Efficacy of Cannabidiol in Patients With Multiple Myeloma, Glioblastoma Multiforme, and GI Malignancies | unknown | Phase 1 / Phase 2 | 160 | Leaf Vertical Inc.INDUSTRY | 1 | Jul 31, 2018 | clinicaltrials |
| NCT02758587 | Study of FAK (Defactinib) and PD-1 (Pembrolizumab) Inhibition in Advanced Solid Malignancies (FAK-PD1) | unknown | Phase 1 / Phase 2 | 59 | NHS Greater Glasgow and ClydeOTHER | 1 | Mar 19, 2018 | clinicaltrials |
| NCT03076372 | A Study Evaluating MM-310 in Patients With Solid Tumors | unknown | Phase 1 | 34 | Merrimack PharmaceuticalsINDUSTRY | 1 | Feb 27, 2018 | clinicaltrials |
| NCT03435289 | A Study of CPI-613 With Gemcitabine and Nab-paclitaxel for Patients With Advanced or Metastatic Pancreatic Cancer | unknown | Phase 1 | 24 | Atlantic Health SystemOTHER | 1 | Feb 19, 2018 | clinicaltrials |
| NCT03098160 | Immunotherapy Study of Evofosfamide in Combination With Ipilimumab | unknown | Phase 1 | 69 | Threshold PharmaceuticalsINDUSTRY | 1 | Oct 30, 2017 | clinicaltrials |
| NCT01971281 | Safety Feasibility and Effect of TTFields (150 kHz) Concomitant With Gemcitabine or Concomitant With Gemcitabine Plus Nab-paclitaxel for Front-line Therapy of Advanced Pancreatic Adenocarcinoma (PANOVA) | unknown | Phase 1 / Phase 2 | 40 | NovoCure Ltd.INDUSTRY | 2 | Sep 13, 2017 | clinicaltrials |
| NCT03236883 | Nonmyeloablative Allogeneic Hematopoietic Stem Cell Transplantation in the Treatment of Pancreatic Cancer(HST) | unknown | Phase 1 | 30 | Tianjin Medical University Cancer Institute and HospitalOTHER | 1 | Aug 2, 2017 | clinicaltrials |
| NCT02349724 | A Clinical Research of CAR T Cells Targeting CEA Positive Cancer | unknown | Phase 1 | 75 | Southwest Hospital, ChinaOTHER | 1 | Apr 25, 2017 | clinicaltrials |
| NCT03013712 | A Clinical Research of CAR T Cells Targeting EpCAM Positive Cancer(CARTEPC) | unknown | Phase 1 / Phase 2 | 60 | First Affiliated Hospital of Chengdu Medical CollegeOTHER | 1 | Jan 6, 2017 | clinicaltrials |
| NCT02839954 | CAR-pNK Cell Immunotherapy in MUC1 Positive Relapsed or Refractory Solid Tumor | unknown | Phase 1 / Phase 2 | 10 | PersonGen BioTherapeutics (Suzhou) Co., Ltd.INDUSTRY | 1 | Dec 6, 2016 | clinicaltrials |
| NCT02587689 | Phase I/II Study of Anti-Mucin1 (MUC1) CAR T Cells for Patients With MUC1+ Advanced Refractory Solid Tumor | unknown | Phase 1 / Phase 2 | 20 | PersonGen BioTherapeutics (Suzhou) Co., Ltd.INDUSTRY | 1 | Dec 5, 2016 | clinicaltrials |
| NCT02506803 | Phase I Study of Neoadjuvant Chemotherapy for Patients With Borderline Resectable Pancreatic Cancer. | unknown | Phase 1 | 10 | Wakayama Medical UniversityOTHER | 1 | May 12, 2016 | clinicaltrials |
| NCT02423239 | A Study of Dexanabinol in Combination With Chemotherapy in Patients With Advanced Tumours | unknown | Phase 1 | 112 | e-Therapeutics PLCINDUSTRY | 4 | Apr 6, 2016 | clinicaltrials |
| NCT02706782 | A Study of Mesothelin Redirected Autologous T Cells for Advanced Pancreatic Carcinoma(meso-CART) | unknown | Phase 1 | 30 | Shanghai GeneChem Co., Ltd.INDUSTRY | 1 | Mar 11, 2016 | clinicaltrials |
| NCT02662348 | T Cell Mediated Adaptive Therapy for Her2-positive Neoplasms of Digestive System | unknown | Phase 1 | 6 | Yi MiaoOTHER | 1 | Jan 25, 2016 | clinicaltrials |
| NCT02133079 | Immunotherapy of Tumor With Autologous Tumor Derived Heat Shock Protein gp96 | unknown | Phase 1 / Phase 2 | 20 | Cure&Sure Biotech Co., LTDINDUSTRY | 1 | Dec 11, 2015 | clinicaltrials |
| NCT01934634 | Phase I Trial of LCL161 and Gemcitabine Plus Nab-Paclitaxel in Metastatic Pancreatic Cancer | unknown | Phase 1 | 24 | US Oncology ResearchINDUSTRY | 1 | Nov 10, 2015 | clinicaltrials |
| NCT02580747 | Treatment of Relapsed and/or Chemotherapy Refractory Advanced Malignancies by CART-meso | unknown | Phase 1 | 20 | Chinese PLA General HospitalOTHER | 1 | Oct 20, 2015 | clinicaltrials |
| NCT01882946 | Safety and Efficacy Study of DCVax-Direct in Solid Tumors | unknown | Phase 1 / Phase 2 | 60 | Northwest BiotherapeuticsINDUSTRY | 1 | Oct 7, 2015 | clinicaltrials |
| NCT02528526 | Effects of OXY111A in Primary and Secondary Hepato-Pancreato-Biliary Neoplasm(OXY1A) | unknown | Phase 1 / Phase 2 | 69 | University of ZurichOTHER | 1 | Aug 19, 2015 | clinicaltrials |
| NCT02024633 | Combination of Icotinib and Gemcitabine as First-line Treatment in Pancreatic Cancer | unknown | Phase 1 | 24 | Betta Pharmaceuticals Co., Ltd.INDUSTRY | 1 | Jul 15, 2015 | clinicaltrials |
| NCT02278458 | Combination of Icotinib and Gemcitabine as First-line Treatment in Pancreatic Cancer | unknown | Phase 1 | 24 | Betta Pharmaceuticals Co., Ltd.INDUSTRY | 1 | May 22, 2015 | clinicaltrials |
| NCT02213419 | Endoscopic Ultrasonography-guided Double Ethanol Lavage for Pancreatic Cysts: a Prospective Cohort Study | unknown | Phase 1 | 40 | Samsung Medical CenterOTHER | 1 | Feb 12, 2015 | clinicaltrials |
| NCT01381822 | Dose-Escalation Study of TH-302 in Combination With Sunitinib to Treat Patients With Advanced Renal Cell Carcinoma,Gastrointestinal Stromal Tumors and Pancreatic Neuroendocrine Tumors(TH-CR-410) | unknown | Phase 1 | 58 | Threshold PharmaceuticalsINDUSTRY | 1 | Apr 21, 2014 | clinicaltrials |
| NCT02042859 | Radiofrequency Probe for Management of Unresectable Bile Duct and Pancreatic Cancer(EndoHPB) | unknown | Phase 1 | 40 | Ochsner Health SystemOTHER | 0 | Jan 23, 2014 | clinicaltrials |
| NCT02038738 | 68Ga-DOTATATE PET Scan Imaging in Patients With Neuroendocrine Tumors | unknown | Phase 1 / Phase 2 | 250 | Ochsner Health SystemOTHER | 1 | Jan 17, 2014 | clinicaltrials |
| NCT00553683 | Cyclophosphamide, Radiation Therapy, and Poly ICLC in Treating Patients With Unresectable, Recurrent, Primary, or Metastatic Liver Cancer | unknown | Phase 1 / Phase 2 | 50 | Rutgers, The State University of New JerseyOTHER | 1 | Jan 14, 2014 | clinicaltrials |
| NCT00010270 | LMB-9 Immunotoxin in Treating Patients With Advanced Pancreatic, Esophageal, Stomach, Colon, or Rectal Cancer | unknown | Phase 1 | 50 | University Hospital FreiburgOTHER | 1 | Dec 19, 2013 | clinicaltrials |
| NCT00024063 | SU006668 in Treating Patients With Advanced Solid Tumors | unknown | Phase 1 | — | Jonsson Comprehensive Cancer CenterOTHER | 0 | Dec 19, 2013 | clinicaltrials |
Data updated 23 days agoSource updated Oct 25, 2021source: clinicaltrials